Triple therapy to boost stroke recovery in Azerbaijan: combining brain stimulation, medication, and physiotherapy

CINEMA study - cerebrolysin neuro modulation Azerbaijan

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN45191532

Enrollment

Registered

2025-02-13

Start date

2024-03-01

Completion date

Unknown

Last updated

2025-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

To study the effectiveness of the use of cerebrolysin in combination with physical methods of treatment (direct current stimulation, kinesitherapy, massage) in the rehabilitation of patients with cerebral stroke. Circulatory System

Interventions

This is a single-centre interventional randomised open-label study design: The study will involve 60 patients with cerebral stroke (CS) in the early (from 3 to 6 months) and late (from 6 months to a y

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Ischemic stroke patients 2. Non-transient arm paresis 3. Aged 18-85 4. Intact cortico-spinal tract 5. Baseline NIHSS above 8.

Exclusion criteria

Exclusion criteria: 1. Progressive or unstable stroke 2. Preexisting or active major neurological or psychiatric disease 3. History of significant alcohol or drug abuse within the previous 3 years 4. Advanced liver, kidney, cardiac, or pulmonary disease 5. Terminal medical diagnosis with an expected survival of <l year 6. Substantial decrease in alertness at the time of randomization 7. Any condition that would represent a contraindication for cerebrolysin administration, including allergy 8. Pregnancy or lactation 9. Participation in another therapeutic study of stroke or stroke recovery

Design outcomes

Primary

Measure	Time frame
Functional activity of the upper limbs is measured using the Action Research Arm Test (ARAT) on the 14th day after the start of treatment	—

Secondary

Measure	Time frame
The following secondary outcome measures are assessed on day 15: 1. The severity of neurological deficit measured using the NIH Stroke Scale/Score (NIHSS) scale 2. Daily life activity measured using the Barthel scale (and Rankin scale) 3. Cognitive functions measured using the Mini-Mental State Examination (MMSE) scale (or Functional Independence Measure (FIM), Montreal Cognitive Assessment (MoCA)) 4. Functional activity of the upper limbs measured using the ARAT 5. Electrical activity of the muscles measured using electromyography (EMG)	—

Measure

Time frame

The following secondary outcome measures are assessed on day 15: 1. The severity of neurological deficit measured using the NIH Stroke Scale/Score (NIHSS) scale 2. Daily life activity measured using the Barthel scale (and Rankin scale) 3. Cognitive functions measured using the Mini-Mental State Examination (MMSE) scale (or Functional Independence Measure (FIM), Montreal Cognitive Assessment (MoCA)) 4. Functional activity of the upper limbs measured using the ARAT 5. Electrical activity of the muscles measured using electromyography (EMG)

—

Countries

Azerbaijan

Contacts

Public ContactSadagat Huseynova

hsadagat@gmail.com+994 12 496-07-06, +994 12 496-07-47, +994 12 496-07-48

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026